CA
NZ
UK
AU
IND
US
Journey Medical Corporation (NASDAQ:DERM) shares were little changed at last closing. Journey Medical is a commercial-stage dermatology pharmaceutical company that markets a portfolio of branded skin-care products and is launching an oral treatment for rosacea.
DexCom, Inc. (NASDAQ:DXCM) shares fell at last closing. DexCom makes continuous glucose monitoring systems for diabetes, along with an over-the-counter biosensor.
Beta Bionics, Inc. (NASDAQ:BBNX) shares fell at last closing after a wave of insider stock sales and a newly filed securities class action added to pressure on the name.BetaBionics is a medical-device company that makes an automated insulin-delivery pump for type 1 diabetes, having …
AIM ImmunoTech Inc. (NASDAQ:AIM), a penny stock, fell at last closing. AIM ImmunoTech is a tiny, pre-revenue clinical-stage biotechnology company whose lead asset, an experimental immunomodulator, is being developed in pancreatic cancer.
Align Technology, Inc. (NASDAQ:ALGN) shares dipped modestly at last closing. Align makes the Invisalign clear-aligner system and iTero intraoral scanners and software for orthodontics and restorative dentistry.
Cytek Biosciences, Inc. (NASDAQ:CTKB), a penny stock, was flat at last closing. Cytek is a life-science tools maker specializing in full-spectrum flow-cytometry instruments and related reagents and services.
Shares of this NASDAQ-listed clinical-stage biotechnology company are down 28.75% in pre-market trading to $17.30, sinking nearly 30% despite the company's own news today being unrelated to any trial failure. The steep drop far outpaces broader healthcare sector weakness, suggesting investors are reacting to …
Ionis Pharmaceuticals (NASDAQ:IONS) shares are down 9.50% in pre-market trading to $52.36, after Novartis (NYSE:NVS), its partner on pelacarsen, an Ionis-developed cardiovascular drug, reported that the Phase 3 Lp(a)HORIZON outcomes trial failed to meet its primary endpoint of reducing cardiovascular events. The disappointing readout, …
Shares of this NASDAQ-listed late-stage biopharmaceutical company are down 8.82% in pre-market trading to $23.16, falling alongside broader weakness across the biotech and lipid-lowering space after a competitor's cardiovascular trial disappointment. The decline reflects sector-wide investor concern about the cholesterol and cardiovascular lipid-lowering drug …
Novartis (NYSE:NVS) shares are down 12.87% in pre-market trading to $139.40, after the company disclosed that its Phase 3 HARBOR trial testing del-desiran in patients with myotonic dystrophy type 1 failed to meet its primary endpoint of improved hand-opening speed versus placebo. This marks …
Please wait processing your request...